Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Starts Operations in New mRNA Vaccine Production Facility

publication date: Dec 29, 2022

Shanghai Everest Medicines has started operations in its $130 million mRNA vaccine production facility, located in Jiashan, Zhejiang Province. In September 2021, Everest announced a $500 million two-part mRNA deal with Providence Therapeutics of Calvary, Canada. Initially, Everest acquired China-Asia rights to Providence's mRNA Phase II COVID-19 vaccine and then began a 50/50 global collaboration for two additional Providence mRNA prophylactic or therapeutic products. Everest said it has completed industrial scale technology transfer of the mRNA platform along with other tasks that will allow it to produce mRNA vaccines and other novel drugs. More details....

Stock Symbol: (HK: 1952)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here